| Calorie Count Goes National New York's calorie-count displays will eventually be on menus across the country, part of a broader effort by Democratic Sen. Kirsten Gillibrand to spread New York's diet and safety standards to the entire U.S. online.wsj.com |
Arena, Orexigen Race for a Fat Opportunity The Burrill Report submits: The race to bring a new obesity treatment to market is heating up as Arena Pharmaceuticals (ARNA) announced a marketing and supply agreement with Eisai (ESALY.PK) worth up to $1.3 billion in payments for its experimental obesity drug lorcaserin and its competitor Orexigen (OREX) announced promising results from a late-stage clinical trial for its experimental drug Contrave the same week. Despite the much talked about obesity epidemic and analyst estimates of a multi-billion dollar market for drugs to treat the condition, the hunt for treatments has been plagued with safety concerns, market withdrawals, and clinical failures. The market research firm Datamonitor referred to obesity in a 2009 report as the “$11 billion market that never was” as it forecast drug sales in the category to reach just $560 million in 2018, far less that the $12.2 billion market opportunity it says is there. The problem, says Datamonitor, is that “current approaches just aren’t good enough to capitalize on this opportunity.” Complete Story » seekingalpha.com |
China Nuokang Bio-Pharmaceutical Inc. Reports Second Quarter 2010 Financial Results (GlobeNewswire) 2Q10 Revenue up 8.8% to RMB82.4 Million YOY us.rd.yahoo.com |
Alexza's Staccato: Setting Up as a New Platform for 'Inhalation Technology' Sheff Station submits:The Staccato technology and loxapine that make up AZ-004 will be on display on October 11th as Alexza (ALXA) looks for approval from the FDA. My previous article focused on how Alexza was clearing hurdles to move into a strong position with the FDA. What this article will do is discuss the history of the Staccato technology and its applicability and use in drug delivery with specific emphasis on AZ-004.Alexza and the Staccato technology was founded by Dr. Alex Zaffaroni. The company was built on the concept of the Staccato technology in use for treating acute and intermittent conditions. Alexza has developed a deep pipeline of products in a short period of time as they have put 5 products into the clinic in only 4 years. Capital constraints have caused Alexza to focus on AZ-004 in 2010. They have (pdf) 2 migraine programs, a pain program, AZ-002 Staccato alprazolane which they studied in panic, and AZ-007 which is part of their sleep program.Complete Story » seekingalpha.com |
Biopharmaceutical Bioniche Life Raising Funds to Expand Oncology Drug Production Proactive Investor submits: Canadian biopharmaceutical company Bioniche Life Sciences (BNHLF.PK) said Monday that it is offering up to 20 million new common shares, under two concurrent financings to be held in Canada and Australia. The share offer in Australia is the lead-up to our plan to list the company on the Australian Securities Exchange,Complete Story » seekingalpha.com |